Kane Biotech Expands Commercial Activities in the United States

Rhea-AI Summary

Kane Biotech (OTC:KNBIF) signed non-exclusive U.S. distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ) on Feb. 19, 2026.

The products are FDA 510(k) cleared and Health Canada approved. Life Biologics will distribute nationally in advanced wound care; Patient Care Medical will cover Louisiana, Mississippi and the Gulf Coast. Preparations for initial shipments are underway in the near term.

Positive

• Signed U.S. distribution agreements with two partners
• FDA 510(k) cleared and Health Canada approved product
• National plus regional reach via Life Biologics and Patient Care Medical
• Initial shipments planned in the near term

Negative

• Agreements are non-exclusive, limiting channel exclusivity
• Patient Care Medical coverage is geographically limited to Gulf Coast states
• No financial terms disclosed for the distribution agreements

WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve^® Antimicrobial Wound Gel^® product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ).

US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel 
and revyve Antimicrobial Wound Gel Spray

These U.S. non-exclusive distribution and sales agreements expand our presence in targeted sales channels and geographic markets. Life Biologics distributes nationally in advanced wound care, while Patient Care Medical distributes within Louisiana, Mississippi and the Gulf Coast specializing in in-hospital and mobile wound care facilities. Preparations are underway for initial shipments in the near term.

“Expanding our U.S. distribution network remains a key priority for the Company,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “These agreements enhance our access to selected U.S. markets and support our near-term commercialization objectives.”

About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve^® addresses both biofilms and wound bacteria. revyve^® Antimicrobial Wound Gel, revyve^® Antimicrobial Wound Gel Spray and revyve^® Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve^® Antimicrobial Wound Gel and revyve^® Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.

Join Kane’s Distribution List & Social Media:

To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.

Follow Kane

Website: kanebiotech.com

LinkedIn: https://www.linkedin.com/company/kanebiotech/

Presentations: https://kanebiotech.com/publications-posters/

For more information:

Dr. Robert Huizinga Interim CEO Kane Biotech Inc. rhuizinga@kanebiotech.com (780) 970-1100	Ray Dupuis Chief Financial Officer Kane Biotech Inc. rdupuis@kanebiotech.com (204) 298-2200

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0d1a42a4-d94c-4ef6-9d38-68980e2c1bf1

FAQ

What distribution agreements did Kane Biotech (KNBIF) announce on Feb. 19, 2026?

Kane Biotech announced non-exclusive U.S. distribution/sales agreements with Patient Care Medical and Life Biologics. According to the company, these target in-hospital, mobile wound care and national advanced wound care channels.

Are revyve Antimicrobial Wound Gel products cleared for sale in the U.S. via KNBIF agreements?

Yes — the revyve Antimicrobial Wound Gel line is cleared by the U.S. FDA via 510(k). According to the company, that clearance supports near-term U.S. commercialization through the new distributors.

Which U.S. regions will Patient Care Medical and Life Biologics cover under KNBIF deals?

Patient Care Medical will distribute in Louisiana, Mississippi and the Gulf Coast; Life Biologics will distribute nationally. According to the company, the partners expand targeted sales channels and geographic markets.

When will Kane Biotech (KNBIF) begin shipments under the new U.S. agreements?

Initial shipments are being prepared in the near term. According to the company, logistical preparations are underway to support early-stage commercial deliveries following the agreements.

Do the KNBIF distribution agreements give exclusive U.S. rights to the partners?

No — the agreements are explicitly non-exclusive. According to the company, this structure allows multiple distribution channels while expanding access to selected U.S. markets.